Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH) is a ubiquitous age-related condition, affecting a significant proportion of men over 50. It's crucial for finals as it's the most common cause of Lower Urinary Tract Symptoms (LUTS) in men. The key pathological feature is the non-malignant hyperplasia of glandular and stromal cells within the prostate's transition zone. This enlargement compresses the urethra, leading to bladder outlet obstruction (BOO). Understanding the distinction between 'storage' (frequency, urgency, nocturia) and 'voiding' (hesitancy, weak stream, terminal dribbling, incomplete emptying) LUTS is vital for diagnosis and management. Unmanaged, chronic BOO can lead to serious complications like renal impairment, making early recognition and appropriate management critical.

BPH development is driven by Dihydrotestosterone (DHT), a potent androgen converted from testosterone by 5-alpha-reductase (Type 2) in the prostate. DHT stimulates prostatic cell growth. The resulting prostatic enlargement causes both a 'static' component (physical compression of the urethra) and a 'dynamic' component (increased smooth muscle tone in the prostate and bladder neck, mediated by alpha-1 adrenoceptors). The bladder compensates by detrusor muscle hypertrophy, but chronic obstruction eventually leads to detrusor decompensation, causing LUTS and potential complications.

Patients present with LUTS, which should be categorised into 'storage' (irritative) and 'voiding' (obstructive) symptoms. The International Prostate Symptom Score (IPSS) is a validated tool to quantify symptom severity and impact. On Digital Rectal Examination (DRE), BPH typically feels smooth, firm, and symmetrically enlarged. It's crucial to differentiate this from the hard, nodular, or asymmetrical feel of prostate cancer. Red flags include haematuria, painful urinary retention, or signs of renal impairment. Common complications include Acute Urinary Retention (AUR) – a urological emergency, chronic urinary retention (often painless, leading to overflow incontinence), recurrent UTIs due to urinary stasis, and bladder stones.

For finals, understand *why* each investigation is done:
- **Bedside:**
- **Digital Rectal Examination (DRE):** Essential for prostate assessment (size, consistency, nodules) and to rule out prostate cancer.
- **IPSS Questionnaire:** Quantifies symptom severity and guides management decisions.
- **Bladder Diary:** Helps distinguish nocturia from polyuria, identifies fluid intake patterns.
- **Bloods:**
- **PSA (Prostate-Specific Antigen):** May be mildly elevated in BPH. Discuss risks/benefits of testing, especially in younger men. Crucial for prostate cancer screening.
- **U&Es (Urea & Electrolytes):** To assess renal function, particularly if chronic retention or obstructive uropathy is suspected.
- **Imaging:**
- **Urinary Tract Ultrasound:** Indicated if renal impairment, recurrent UTIs, or suspected bladder stones. Can assess kidney size, hydronephrosis, and bladder wall thickness.
- **Special Tests:**
- **Uroflowmetry:** Measures urine flow rate. A peak flow rate <10-15 mL/s suggests obstruction.
- **Post-void Residual Volume (PVR):** Measured by bladder scan or catheterisation. PVR >100-150 mL is significant and indicates incomplete bladder emptying.

Management is stepwise, based on symptom severity and impact:
- **Conservative (for mild/bothersome symptoms):**
- Lifestyle modifications: reduce caffeine, alcohol, evening fluid intake.
- 'Timed voiding' or 'double voiding' techniques.
- Reassurance and education.
- **Medical (for moderate/severe symptoms):**
- **Alpha-blockers (e.g., Tamsulosin 400mcg OD, Alfuzosin):** First-line. Relax smooth muscle in prostate and bladder neck, rapidly improving flow. Side effects: postural hypotension, retrograde ejaculation, dizziness.
- **5-alpha-reductase inhibitors (e.g., Finasteride 5mg OD, Dutasteride):** Reduce prostate volume by inhibiting DHT production. Slower onset (up to 6 months). Side effects: erectile dysfunction, reduced libido, gynaecomastia. Often used for larger prostates (>30-40g).
- **Combination therapy:** Alpha-blocker + 5-alpha-reductase inhibitor for significant symptoms and large prostates.
- **Surgical (for refractory symptoms, complications, or patient preference):**
- **Transurethral Resection of the Prostate (TURP):** 'Gold standard' for many years. Removes obstructing prostatic tissue endoscopically. Risks: bleeding, TURP syndrome (hyponatraemia), retrograde ejaculation, erectile dysfunction.
- **Newer techniques:** Holmium Laser Enucleation of the Prostate (HoLEP), Urolift, Rezum – generally less invasive with quicker recovery, often preferred for specific prostate sizes or patient profiles.